We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Drug Products » Responding to Compounding Pharmacy Inspections - Webinar CD/Transcript

Other Options

Audio CD/Transcript - Jan. 25, 2017

$287.00

Audio CD/Transcript - Jan. 25, 2017

$258.00

Audio CD/Transcript - Jan. 25, 2017

$244.00

Audio CD/Transcript - Jan. 25, 2017

$230.00

Audio CD/Transcript - Jan. 25, 2017

$215.00

Responding to Compounding Pharmacy Inspections - Webinar CD/Transcript

$287.00
Drug Products

Product Details

Responding to Compounding Pharmacy Inspections

The FDA is looking to shed light on the sometimes murky rules governing compounding  operations primarily regulated on the state level, only adhering to USP 797 Pharmaceutical Compounding — Sterile Preparations.

In April 2016 the agency released three draft guidances addressing multiple facets of the compounding industry including: what constitutes a large-scale compounding facility… associated GMP requirements… standards for hospital compounding… and requirements for compounding without a prescription.

All three guidances emphasize that all products manufactured by outsourcing facilities must comply with GMP rules or be deemed in violation.

If you want to know how these guidances might affect your company, plan on listening to Responding to Compounding Pharmacy Inspections. This 90-minute session will:

  • Identify the latest areas of FDA enforcement in compounding pharmacies
  • Compare requirements of 503A (traditional compounder) and 503B (outsourcing facility)
  • Review USP 797 vs. GMP requirements
  • Identify the constitution of your core FDA Inspection Team
  • Allow you to create the outline of an appropriate FDA response

Order today and be informed about compounding facility inspections.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing